Tumor Infiltrating Lymphocytes (TILs) and Tumor Budding in Invasive Breast Carcinoma: Correlation with Known Prognostic Parameters TIL and Tumor budding in IBC

Arghya Bandyopadhyay (1), M Pallavi Krishna (2)
(1) Department of Pathology, NRS Medical College, Kolkata, West Bengal, India, India,
(2) Department of Pathology , Burdwan Medical College, West Bengal, India, India


Background: Invasive breast cancer (IBC) has long been thought as non-immunogenic, but in recent decades it has been reported that tumour micro-environment (TME) in breast cancer encompasses tumor-infiltrating lymphocytes (TILs), which help in creating anti-tumor immune response. On the other hand, tumor buddings (TB) from the invasive front of the tumor contribute to invasion and metastasis. We aim to evaluate TILs and TB in IBC and to correlate them with known prognostic parameters.

Methods: In this retrospective study, 50 cases of IBC were included. TILs and TB were observed and graded in H&E Stained slides following standard guidelines. Associations of TILs and TB with known clinicopathological parameters were established by statistical methods.

Results: The majority of cases were invasive breast carcinoma (IBC)-NST (78%). The cases with low TILs (involving <50% of stroma) had a significant correlation with positive lymph node metastasis (P = 0.017) and high-grade TB (P = 0.038). TB was associated with other adverse prognostic parameters such as tumor necrosis (P=0.043) and lympho-vascular invasion (LVI) (P=0.033) and large tumor size.

Conclusion: As tumor budding is associated with known poor prognostic factors such as necrosis, LVI and large tumor size, it can be regarded as a potential biomarker in predicting the aggressiveness of breast cancer. Low TILs are positively associated with invasion and lymph node metastasis of IBC. Thus, assessment of these protumor (TB) and antitumor (TILs) factors could be a promising approach for future research on breast cancer.

Full text article

Generated from XML file


Siegel R. Naishadham D. Jemal A. Cancer statistics, 2013. CA Cancer Clin 2013:63:11-30. doi: 10.3322/caac.21590.

Jemal A. Bray F. Center MM, Ferlay J, Ward E. Forman D, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. doi: 10.3322/caac.20107

Burugu S. Asleh-Aburaya K. Nielsen T.O. Immune infiltrates in the breast cancer microenvironment: Detection, characterization and clinical implication. Breast Cancer 2017, 24, 3-15. doi: 10.1007/s12282-016-0698-z

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol 2015;26:259-71. doi: 10.1093/annonc/mdu450.

Lee HJ, Park IA, Song IH, Shin SJ, Kim JY, Yu JH, et al. Tertiary lymphoid structures: Prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol 2016;69:422-30. doi: 10.1136/jclinpath-2015-203089.

Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010:28:105-13. doi: 10.1200/JCO.2009.23.7370.

Yu X, Zhang Z. Wang Z. Wu P. Qiu F. Huang J. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. Clin Transl Oncol. 2016:18:497-506. doi: 10.1007/s12094-015-1391-y.

Tse BW, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ. From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int. 2014;2014:981434. doi: 10.1155/2014/981434.

Marrone KA, Brahmer JR. Immune checkpoint therapy in non-small cell lung cancer. Cancer J. 2016;22:81-91. doi: 10.1097/PPO.0000000000000178.

Robert C, Schachter J, Long GV, Arance A, Grob J. Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-32. doi: 10.1056/NEJMoa1503093.

El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7(1):150. doi: 10.1038/s41523-021-00346-1.

Valenza C, Taurelli Salimbeni B, Santoro C, Trapani D, Antonarelli G, Curigliano G. Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. Cancers. 2023;15(3):767. doi: 10.3390/cancers15030767.

Angelico G, Broggi G, Caltabiano R, Santoro A, Spadola S, D’Alessandris N, et al. Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer. Applied Sciences. 2021; 11(15):6788.

Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. Oncotarget 2010; 1:651-61. doi: 10.18632/oncotarget.199.

Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007:50:151-62. doi: 10.1111/j.1365-2559.2006.02551.x.

Roh MS, Lee JI, Choi PJ. Tumor budding as a useful prognostic 16 marker in esophageal squamous cell carcinoma. Dis Esophagus 2004:17:333-7. doi: 10.1111/j.1442-2050.2004.00436.x.

Kumarguru BN, Anikode SR, Shahanuma S, Aruna K, Venugopal SS, Prashant, BM. Tumor budding in invasive breast cancer – An indispensable budding touchstone. Indian Journal of Pathology and Microbiology 2020;63(5):117-122. doi: 10.4103/IJPM.IJPM_731_18.

Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013 ;39(1):11-26. doi: 10.1016/j.immuni.2013.07.008..

Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer--ready for diagnostic practice? Hum Pathol. 2016;47(1):4-19. doi: 10.1016/j.humpath.2015.08.007.

Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z. The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract. 2013;209(5):269-75. doi: 10.1016/j.prp.2013.01.009.

Gujam FJ, McMillan DC, Mohammed ZM, Edwards J, Going JJ. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. Br J Cancer. 2015 ;113(7):1066-74. doi: 10.1038/bjc.2015.287.

Salhia B, Trippel M, Pfaltz K, Cihoric N, Grogg A, Lädrach C, Zlobec I, Tapia C. High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Res Treat. 2015;150(2):363-71. doi: 10.1007/s10549-015-3333-3.

Lugli A, Karamitopoulou E, Panayiotides I, Karakitsos P, Rallis G, Peros G et al. CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009 ;101(8):1382-92. doi: 10.1038/sj.bjc.6605318.

DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91-102. doi: 10.1016/j.ccr.2009.06.018.


Arghya Bandyopadhyay
drarghyabanerjee@yahoo.com (Primary Contact)
M Pallavi Krishna
Author Biography

Arghya Bandyopadhyay, Department of Pathology, NRS Medical College, Kolkata, West Bengal, India

Associate Professor, Department of Pathology

(West Bengal University of Health Sciences)

NRS Medical College, Kolkata,  West Bengal, India.

Bandyopadhyay A, Krishna MP. Tumor Infiltrating Lymphocytes (TILs) and Tumor Budding in Invasive Breast Carcinoma: Correlation with Known Prognostic Parameters : TIL and Tumor budding in IBC. Arch Breast Cancer [Internet]. 2023 May 20 [cited 2023 Oct. 4];10(3):241-7. Available from: https://www.archbreastcancer.com/index.php/abc/article/view/688

Article Details

Most read articles by the same author(s)